Tumor Biology

, Volume 36, Issue 3, pp 1791–1795 | Cite as

Impact of MDM2 gene polymorphism on sarcoma risk

  • Dawei Zhang
  • Yuanyuan Ding
  • Zhenlin Wang
  • Yan Wang
  • Guangyue Zhao
Research Article


A T>G single nucleotide polymorphism (SNP, rs2279744) of the MDM2 gene has been investigated in sarcoma community, but the findings are conflicting. This study was designed to well define the relationship between SNP rs2279744 and sarcoma risk. We did a systematic computerized search of the PubMed, Web of Science, and Science Direct databases to identify the human case–control studies investigating the relationship between SNP rs2279744 and sarcoma risk with complete genetic data. Pooled odds ratios (ORs) were calculated with the Mantel–Haenszel fixed-effect model or the DerSimonian and Laird random effects model to estimate the risk of sarcoma. Overall analysis included five independent studies. On the whole, the T/G genotype or the combined G/G and T/G genotypes appeared to be associated with approximately 1.40-fold higher risk of sarcoma relative to the T/T genotype (T/G vs. T/T: OR 1.33, 95 % CI 1.00–1.77; G/G + T/G vs. T/T: OR 1.42, 95 % CI 1.08–1.85). We noted that the Caucasian populations showed a similarly increased risk of sarcoma ascribed to the carriage of the same genotypes (T/G vs. T/T: OR 1.41, 95 % CI 1.05–1.90; G/G + T/G vs. T/T: OR 1.49, 95 % CI 1.13–1.97). This meta-analysis provides evidence that MDM2 SNP rs2279744 may be significantly associated with increased risk of sarcoma in Caucasian individuals.


MDM2 Sarcoma SNP Risk 


  1. 1.
    Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(1 Suppl):203–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Borden EC et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003;9(6):1941–56.PubMedGoogle Scholar
  3. 3.
    Hollstein M et al. p53 mutations in human cancers. Science. 1991;253(5015):49–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1(14):1001–8.PubMedGoogle Scholar
  6. 6.
    Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95–107.CrossRefPubMedGoogle Scholar
  7. 7.
    Huang SF et al. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2009;45(1):16–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13(1):49–58.CrossRefPubMedGoogle Scholar
  9. 9.
    Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev. 2006;20(2):125–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Greenblatt MS et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54(18):4855–78.PubMedGoogle Scholar
  11. 11.
    Jones SN et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998;95(26):15608–12.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein–thirty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1999;59(1):1–7.PubMedGoogle Scholar
  13. 13.
    Bond GL et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.CrossRefPubMedGoogle Scholar
  14. 14.
    Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Thurow HS et al. Ewing sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs. Mol Biol Rep. 2013;40(8):4929–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Tornesello ML et al. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients. Biomarkers. 2011;16(1):42–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Toffoli G et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15(10):3550–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Alhopuro P et al. The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42(9):694–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedGoogle Scholar
  20. 20.
    Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;47:15–7.Google Scholar
  21. 21.
    Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57.CrossRefPubMedGoogle Scholar
  22. 22.
    Leach FS et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53(10 Suppl):2231–4.PubMedGoogle Scholar
  23. 23.
    Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55(1):96–107.CrossRefPubMedGoogle Scholar
  24. 24.
    Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004;2(1):1–8.PubMedGoogle Scholar
  25. 25.
    Oliner JD et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Cordon-Cardo C et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54(3):794–9.PubMedGoogle Scholar
  27. 27.
    Birgander R et al. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996;46(3):148–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Arva NC et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005;280(29):26776–87.CrossRefPubMedGoogle Scholar
  29. 29.
    Ruijs MW et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007;15(1):110–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Cai X, Yang M. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol. 2012;138(4):555–61.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Dawei Zhang
    • 1
  • Yuanyuan Ding
    • 2
  • Zhenlin Wang
    • 3
  • Yan Wang
    • 1
  • Guangyue Zhao
    • 1
  1. 1.Department of Orthopedics, Xi Jing HospitalThe Fourth Military Medical UniversityXi’anChina
  2. 2.Department of PharmacyGeneral Hospital of Beijing Military Area CommandBeijingChina
  3. 3.Department of Orthopedic SurgeryThe No. 113 Hospital of PLANingboChina

Personalised recommendations